Beam Therapeutics  logo
Beam Therapeutics BEAM
$ 28.43 -2.94%

Quarterly report 2025-Q3
added 11-04-2025

report update icon

Beam Therapeutics Cash Flow 2011-2026 | BEAM

Annual Cash Flow Beam Therapeutics

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Operating Cash Flow

-347 M -149 M 22.5 M -66.3 M -95.7 M -72 M - - - - - - - -

Depreciation & Amortization

21.9 M 20 M 14.1 M 7.45 M 4.74 M 3.5 M - - - - - - - -

Accounts Payables

3.87 M 1.62 M 9.03 M 7.47 M 6.31 M - - - - - - - - -

All numbers in USD currency

Quarterly Cash Flow Beam Therapeutics

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

- - -104 M - - - -99.7 M - - - -110 M - 91.7 M 166 M 218 M - -68.1 M -71.1 M -38.6 M - -71.4 M -50.2 M -27.4 M - -54.2 M -37.2 M -25.9 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Depreciation & Amortization

5.56 M 5.54 M 5.53 M - 5.48 M 5.58 M 5.43 M - 5.19 M 4.82 M 4.65 M - 3.47 M 3.42 M 3.31 M - 4.82 M 3.07 M 1.4 M - 3.46 M 2.24 M 1.1 M - 908 K 858 K 735 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Accounts Payables

9.54 M 10.6 M 7.7 M 3.87 M 3.81 M 4.43 M 2.79 M 1.62 M 3.18 M 6.89 M 14.1 M 9.03 M 7.02 M 7.1 M 6.27 M 7.47 M 7.28 M 8.03 M 7.98 M 6.31 M 6.31 M 6.31 M 6.31 M 7.85 M 7.85 M 7.85 M 7.85 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Beam Therapeutics , reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adagene Adagene
ADAG
$ 2.8 -3.69 % $ 158 M chinaChina
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 80.89 -1.35 % $ 1.56 B usaUSA
Amgen Amgen
AMGN
$ 341.41 -0.45 % $ 183 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Aytu BioScience Aytu BioScience
AYTU
$ 2.68 3.88 % $ 16.8 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.23 -1.01 % $ 7.77 B australiaAustralia
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Biogen Biogen
BIIB
$ 177.21 0.61 % $ 25.8 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 224.26 0.14 % $ 5 B danmarkDanmark
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 115.04 -1.49 % $ 27.2 B germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
$ 9.65 - $ 1.52 B britainBritain
Arrowhead Pharmaceuticals Arrowhead Pharmaceuticals
ARWR
$ 68.78 -0.5 % $ 9.2 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
$ 1.01 1.6 % $ 137 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 9.79 -3.55 % $ 644 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Bellicum Pharmaceuticals Bellicum Pharmaceuticals
BLCM
- -9.72 % $ 5.89 M usaUSA
Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc
ADAP
- -15.15 % $ 60.3 M britainBritain
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.0 -3.61 % $ 8.7 B israelIsrael
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.0 -0.78 % $ 4.33 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.28 -1.94 % $ 421 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA